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esophageal squamous cell carcinoma (ESCC) patients 
including this group of tumors that had been excluded in the 
previous randomized studies. 
 
Material and Methods: A total of 202 patients who were 
diagnosed with stage II-III thoracic ESCC initiated NACRT 
between January 2003 and July 2014. Among them, 9 
patients refused further treatment during the course of 
NACRT and finally 200 patients were analyzed. For clinical 
staging, endoscopic ultrasonography was performed in 116 
(58.0%) and FDG PET/CT in all patients. 75 patients (37.5%) 
had supraclavicular or celiac LN metastasis, which staged as 
M1a (N=54, 27.0%) or M1b (N=21, 10.5%) according to the 6th 
edition of AJCC staging. 168 patients (84.0%) completed both 
NACRT and surgery, 79 (47.0%) of whom underwent 2 field LN 
dissection while 89 (53.0%) received 3 field LN dissection. 
Prognostic factors for survival were assessed using Cox 
regression. 
 
Results: After the median 17.8 months’ follow-up, patients 
(%) experienced disease progression and (%) died. In all 
patients, the 2-year locoregional control (LRC), disease free 
survival (DFS), and overall survival (OS) rates were %, 47.8%, 
and 67.9%, respectively. Following surgery, the pathologic 
complete response was achieved in 44 (26.2%) patients. In 
multivariate analysis, 3 field LN dissection (p=0.0439), ypT0 
(p=0.0380), ypN0 (p=0.0024), and negative surgical margin 
(p=0.0037) were favorable prognostic factors for DFS and 
negative surgical margin (p<0.0001) and age < 60 years 
(p=0.0411) were favorable factors for OS. The metastasis to 
supraclavicular and/or celiac LN was not significant factor for 
and DFS (p=0.5584) and OS (p=0.5874). 
 
Conclusion: Celiac and/or supraclavicular LN metastasis did 
not compromise treatment outcomes significantly following 
NACRT and surgery in selected patients who tolerates the 
trimodality treatment. 
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Purpose or Objective: Cancer of the gastroesophageal 
junction (GEJ) has been rising in incidence in recent years. 
The role of radiation therapy (RT) in the treatment of GEJ 
cancer remains unclear, as the largest prospective trials 
advocating for either adjuvant or neoadjuvant 
chemoradiotherapy (CRT) combine GEJ cancer with either 
gastric or esophageal cancer. The aim of the present study is 
to examine the effect of neoadjuvant versus adjuvant 
treatment on overall and disease-specific survival for 
patients with surgically resected cancer of the true GEJ 
(Siewert type II). 
 
Material and Methods: The Surveillance, Epidemiology, and 
End Results (SEER) registry database (2001-2011) was queried 
for cases of surgically resected Siewert type II 
gastroesophageal junction cancer. The variables obtained for 
each case include patient demographics (race/ethnicity, sex, 
age at presentation, year of diagnosis), disease 
characteristics (histologic grade, surgical stage/extent of 
disease, nodal status of the disease, presence of distant 
metastases), and treatment modalities (radiation sequence 
relative to surgery, type of surgery performed, and type of 
radiation administered). Patients with metastatic disease, no 
surgical intervention, and missing data were excluded from 
the cohort. 1497 patients with resectable GEJ cancer were 
identified, with 746 receiving adjuvant RT and 751 receiving 
neoadjuvant RT. Retrospective analysis was performed with 
the endpoints of overall and disease-specific survival. 
 
Results: Using cox regression and controlling for independent 
covariates (age, sex, race, stage, grade, histology, and year 
of diagnosis), we showed that adjuvant RT resulted in 
significantly lower death risk (hazard ratio [HR], 0.84; 95% 
confidence interval 0.73-0.97; p-value=0.0168) and 
significantly lower disease-specific death risk (HR, 0.84; 95% 
confidence interval, 0.72-0.97; p-value=0.0211) 
 
Conclusion: This analysis of SEER data showed a survival 
benefit for the use of adjuvant RT over neoadjuvant RT for 
the treatment of Siewert type II GEJ cancer. We suggest 
future prospective studies to compare outcomes of adjuvant 
versus neoadjuvant treatment for true GEJ cancer. 
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Purpose or Objective: We hypothesized that selected cases 
among patients with localized ALN recurrence in gastric 
cancer (GC) might be salvaged by integration of radiotherapy 
(RT) in the multimodal treatment. 
 
Material and Methods: We retrospectively identified patients 
with isolated ALN recurrence from GC between 2005 and 
2013. We categorized patients into two groups by treatment 
approach after diagnosis of ALN recurrence: those who 
treated with integration of RT to chemotherapy (RCT group) 
vs. those who received systemic chemotherapy only (CT 
group). 
 
Results: Of 53 patients with ALN recurrence from GC, 31 
patients were classified as RCT group and 22 as CT group. 
The isolated distant failure (DF; 11/31, 35.5%) was dominant 
pattern of failure (POF) in the RCT group (median DF-free, 26 
months). While local progression (LP) followed by DF (7/22, 
31.8%) was dominant POF in the CT group, in which LP 
(median LP-free, 8 months) occurred earlier than DF (median 
DF-free, 18 months). RCT group had significantly prolonged 
median PFS compared with CT group (25 vs. 8 months, p = 
0.021). In multivariate analysis, the treatment group was 
identified as independent prognostic factor related to PFS (p 
= 0.013). There was a borderline significance in OS between 
RCT group and CT group (29 vs. 20 months, p = 0.095). 
 
Conclusion: Integration of RT and chemotherapy influenced 
the pattern of failure, and significantly improved PFS with 
isolated ALN recurrence in recurrent GC. RT may be 
considered in the treatment course of isolated ALN 
recurrence. 
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Purpose or Objective: To review the treatment result of 
metachronous esophageal cancer (ESC) after head and neck 
cancer (HNC). 
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Material and Methods: This study reviewed cancer registry 
data of our hospital from 2004 to 2012 with following 
inclusion criteria: ESC were found at least 90 days after HNC 
in the same patient, and both were diagnosed with pathology 
of invasive cancer. Patients would be excluded with following 
criteria: ESC was an extension of HNC or vice versa, and no 
available information of treatment could be retrieved. 
Treatment was composed by combinations of radiotherapy, 
chemotherapy, and surgery depending on disease status and 
performance status of the patient. The primary end point 
was overall survival (OS), and the second endpoint was 
progression-free survival (PFS). 
 
Results: 77 patients were eligible. The median time from 
HNC to ESC was 32 months (4 – 147 months). Fifty-three 
patients (60%) were stage III/IV and 15 patients received best 
supportive care only after diagnosis of ESC. After excluding 
the BSC group, the 2-year OS were 34.9%. Fifteen patients 
were alive and one of them still had ESC. Thirty-five, 10, and 
2 patients died from ESC, treatment related complications, 
and other disease, respectively. Univariate analysis revealed 
that ECOG > 1, tube feeding, anemia, and no esophagectomy 
correlated with poor OS (p < 0.05). Multivariate analysis 
showed that lower hemoglobin level, habit of smoking, ECOG 
score = 2, and no esophagectomy were independent poor 
prognostic factors (p < 0.05). The 2-year PFS rate for all 
patients was 30.7%. In the univariate analysis, ECOG > 1, tube 
feeding, body weight loss > 5%, anemia, no esophagectomy, 
and ESCstage III/IV were significantly correlated with poor 
PFS (p < 0.05). In the multivariate analysis, anemia and no 
esophagectomy were independently correlated with tumor 
recurrence (p < 0.05). Treatment outcome of patients who 
received esophagectomy were similar to ESC patients without 
prior history of HNC. The 2-year OS and PFS were 63.9% and 
50.6%, respectively. Both were significantly higher than 
patients who did not receive esophagectomy (11.8% and 9.9%, 
p < 0.01). 
 
Conclusion: the treatment result of metachronous ESC after 
HNC varied with disease and patient status. If esophagectomy 
was possible, the treatment outcome was not inferior to 
esophageal cancer without prior head and neck cancer 
history. But the treatment outcome was poor in patients with 
unresectable disease or poor performance status. A screening 
program for metachronous ESC should be considered for high 
risk patients to detect resectable ESC and improve treatment 
outcome. 
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Purpose or Objective: Evaluate the salvage radiotherapy 
outcome in patients with supraclavicular lymph node 
metastases (SCLN) after esophagectomy. 
 
Material and Methods: A total of 117 patients with 
esophageal squamous cell carcinoma after initial 
esophagectomy (R0 resection) were retrospectively analyzed 
and they were diagnosed supraclavicular lymph node 
metastases during follow-up time. All patients were divided 
into salvage radiotherapy group (SR, n=89) and no salvage 
radiotherapy group (NSR, n=27). 
 
Results: The 1,3,5-year overall survival rates were 
81.6%、31.4%、8.6%, respectively. In all patients the 1,3-year 
survival time after SCLN metastasis (ASMS) rates were 
40.2%、14.5%, and the median ASMS time was 10 months. 
The 1, 3-year ASMS rates were 48.1%、18.9% in SR group and 
12.0%、0% in NSR group,respectively (P<0.001). In SR group, 
the 1, 3-year ASMS rates in the patients with combined 
radiochemotherapy and single radiotherapy were 62.6%, 
33.4% and 41.9%, 16.5% (P<0.001). In the subgroup analysis, 
in combining visceral metastases group (CVM), the 1,3-year 
ASMS rates were 35.5% , 0%, and 42.3%, 21.5% in no 
combining visceral metastases group (NCVM) (P = 0.004). The 
3-year ASMS rate with the patients in no combining 
mediastinal failure group (NCMF) (22.2%) was higher than 
those in combining mediastinal failure group (CMF) (7.0%) 
(p=0.041). According to the salvage radiation dose, the 1,3-
year ASMS rates were 56.5%, 23.4% in ≥60Gy group and 29.2%, 
7.5% in <60Gy group (p<0.001). Multivariate factor analysis 
revealed that combining visceral metastases, combining 
mediastinal failure, salvage radiotherapy, salvage radiation 
dose and salvage treatment model may be considered 
favourable prognostic factors. 
 
Conclusion: Salvage radiotherapy may improve survival of 
patients with supraclavicular lymph node metastases after 
esophagectomy. Combined radiochemotherapy and no 
combining visceral metastases and a salvage radiation dose 
≥60 Gy were associated with a better prognosis for those 
patients. 
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Purpose or Objective: To evaluate the correlation between 
radiation dose and locoregional control (LRC) for patients 
with stage II-III esophageal cancer treated with definitive 
concurrent chemo-radiotherapy (CCRT). 
 
Material and Methods: The medical records of 236 patients 
with clinical stage II and III esophageal cancer treated with 
definitive CCRT at the Yonsei Cancer Center between Feb 
1994 and May 2013 were retrospectively reviewed. Among 
these patients, 120 received a radiation dose of < 60 Gy 
(standard-dose group), while 116 received a radiation dose of 
≥ 60 Gy (high-dose group). The median dose of radiation in 
the standard and high dose groups was 50.4 Gy (range, 45.0-
59.4 Gy) and 63 Gy (range, 60.0-66.6 Gy). Concurrent 5-
FU/cisplatin (FP) chemotherapy (CHT) was performed in 82.2 
% of patients. 
 
Results: The patient characteristics had no differences in 
age, sex, pathology, grade, tumor length, and clinical stage 
between the two groups. Patients with high Karnofsky 
performance status scale and lower thoracic esophageal 
tumor were included more in standard dose group (p = 0.017 
and 0.038). Maintenance CHT was performed more in 
standard dose group (45% versus 30.2%, p = 0.037) and FP 
CHT was more frequently used in high dose group (76.7% vs. 
87.9%, p = 0.019). The median follow-up time for all patients 
was 19.2 months (range, 2.2-164.7). Of all patients, 2-yr and 
5-yr LRC rate were 60.0% and 48.4%. The median progression-
free survival (PFS) and overall survival (OS) were 13.2 months 
and 26.2 months, respectively. Patients in the high-dose 
group had a significantly better LRC (2-yr LRC rate, 50.3% vs. 
69.1%, p = 0.002), PFS (median, 11.7 vs. 16.7 months, p = 
0.029) and OS (median, 22.3 vs. 35.1 months, p = 0.043). The 
complete clinical response (CR) rate was significantly higher 
in the high-dose group (44.2% vs. 62.1%, p = 0.007). The 
treatment-related toxicities did not show a significant 
difference between the both groups (p = 0.936), although it 
was difficult to assess due to a retrospective fashion. On 
multivariate analysis, sex (female), radiation dose (≥ 60 Gy) 
and use of maintenance CHT were independent predictors for 
improved LRC, and sex (female), clinical stage (stage II vs. 
III), radiation dose (≥ 60 Gy) and use of maintenance CHT 
were significant predictive factors for OS. 
 
Conclusion: A higher radiation dose of > 60 Gy is associated 
with increased LRC, PFS and OS for patients with stage II-III 
esophageal cancer treated with definitive CCRT. 
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